Annual report [Section 13 and 15(d), not S-K Item 405]

Segment Information - Schedule of Profit and Loss from Segments (Details)

v3.26.1
Segment Information - Schedule of Profit and Loss from Segments (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Research and development expenses:    
Personnel $ 46,934 $ 39,239
Clinical trials 39,581 22,286
Development Services 15,350 16,417
Manufacturing of preclinical and clinical supplies 38,240 15,523
License of intellectual property 0 1,523
Other research and development costs [1] 2,569 2,215
General and administration expenses 29,567 27,938
Interest income (6,031) (10,025)
Interest expense 2,004 748
Other income, net (358) 0
Net loss $ 167,856 $ 115,864
[1] Other research and development costs includes costs associated with information technology, travel, medical and scientific symposiums and conferences.